Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
BeyondSpring Inc. 2025 Annual Report – Plinabulin Clinical Progress, SEED TPD Platform, and Strategic Collaborations with Eli Lilly & Eisai
BeyondSpring Inc. has filed its 2025 Annual Report (Form 10-K), detailing key investor highlights including its clinical-stage cancer therapies, strategic developments, and financial standing. The report outlines the company’s progress with product candidates like DUBLIN-3, its staged dilution of equity interest in SEED Therapeutics, and the associated research collaborations with Eli Lilly and Eisai. It also emphasizes significant risk factors such as regulatory approvals, financing needs, and compliance with Nasdaq listing requirements, urging investors to conduct thorough due diligence.